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 Due to their small size, nanoparticles (NPs) are a suitable platform for building the next-
generation targeted therapy for cancer. The high surface-to-volume ratio and well-studied surface 
chemistry of NPs allow for efficient loading of treatment and targeting moieties, which would 
maximize drug delivery and ensure high tumor specificity, all the while sparing healthy tissue. 
Silica-coated superparamagnetic iron oxide (SPIO) nanoparticles, a type of magnetic resonance 
imaging (MRI) contrast agent, combine the small size of nanomaterial with the benefits of MRI 
to provide a non-invasive method for tracking NPs inside the human body. Relaxivity studies of 
NPs revealed that T2 relaxivity of SPIO NPs were suitable for clinical use, at above 100 mM-1s-1. 
Previous efforts successfully synthesized silica-coated SPIO NPs with a diameter of 
approximately 23 nm and a shell thickness of 4 nm using a reverse micro-emulsion method. 
Current studies focus on attaching a monoclonal antibody (As33), which targets glycoprotein 
A33, a tumor antigen that is over-expressed in certain pancreatic cancer cells, onto silica-coated 
NPs. Evidence of cellular particle uptake using fluorophore-labeled, As33-conjugated silica-
coated NPs was observed in pancreatic cancer cells that over-expressed A33 in both 2D and 3D 
cell culture. In order to study live cells, an MR imaging phantom was designed and constructed 
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By the beginning of the twenty-first century, cancer had become the second leading cause of 
death in the United States, trailing only behind heart disease.1 With a five-year survival rate of less 
than 6%, pancreatic cancer is one of the deadliest cancers.2 It is considered, for the most part, 
incurable. The poor prognosis of pancreatic cancer is a combination of the difficulties of detection in 
the early stages and the fact that current therapeutic options are unable to improve long-term survival 
rates. Moreover, available treatments target both healthy and cancerous cells, causing many 
undesired side-effects ranging from nausea to severe neurotoxicity.  
 This study is a part of the efforts at Wellesley College to develop a new form of targeted 
cancer therapy using nanoparticles (NPs), specifically, for treating pancreatic cancer. However, the 
design of our nano-vehicle has theranostic potential 
and can be modified easily to accommodate the 
needs for treating other types of cancers or 
individual patients. The properties of the NPs offer 
several advantages as a promising drug delivery 
system. First of all, NPs can enter cells via 
endocytosis.4 Ranging between 10–100 nm in 
diameter, the high surface-to-volume ratio of NPs 
provides a platform for efficiently attaching 
targeting and therapeutic moieties. With 
superparamagnetic iron oxide (SPIO) as their core, 
NPs can also act as a magnetic resonance imaging 
(MRI) contrast agent that allows the vehicle to be 
tracked non-invasively in the body. To avoid early clearance by lymphocytes, NPs are coated prior to 
Figure 1. Schematic diagram of the proposed 
antibody-conjugated (CHO31.1 or As33), silica-
coated iron oxide nanoparticles, which will act as 
the platform for attaching therapeutic agents such 
as the 10B-loaded polyGL for boron-neutron 
capture therapy (BNCT). The fluorophore-tagged 
antibody is linked to the nanoparticles (NPs) surface 
via polyethylene glycol (PEG), a polymer known to 





further functionalization (Figure 1).5 Previous work to coat NPs with gold encountered roadblocks in 
creating a complete coating on the bare SPIO cores.6 Particles with incomplete coating were difficult 
to functionalize and the silica coating was explored as an alternative.7 Silica-coated SPIO NPs are 
non-toxic to cells and are cheaper to make than gold-coated NPs, which give them an additional 
economic advantage over gold-coated NPs.8 
Three types of molecules are used to functionalize the NP surface (Figure 1). A monoclonal 
antibody (CHO31.1 or As33) is linked via a polyethylene glycol (PEG) polymer to the NP to enable 
the targeting of glycoprotein A33 (GPA33), a protein over-expressed on >95% of colorectal cancers 
and >50% of pancreatic cancer cells.9 Moreover, boronated poly-GL peptides are attached as the 
therapeutic element to allow for boron-neutron capture therapy (BNCT).10 By providing a source of 
thermal neutrons (neutrons with 0.025 eV or lower) to a non-radioactive isotope of boron, 10B, alpha 
radiation is released in a reaction as follows:11 
 𝐵!!" +    𝑛!! → 𝐵!!! → 𝛼!! + 𝐿𝑖 + 2.79  𝑀𝑒𝑉!!                                                     [1] 
Although alpha radiation is highly lethal, alpha particles move rather slowly and their range of 
damage is limited to a distance approximately equal to the diameter of a cell.10, 11b Once entering the 
cell, radioactive-boron would kill cancerous cells while sparing the healthy tissue, as tumor cells will 
have accumulated more boron than normal cells.10  
Previously, silica-coated SPIO NPs were successfully synthesized to have a diameter of 
approximately 50 nm and a shell thickness of 10-20 nm using a reverse micro-emulsion method.12 
Relaxivity studies revealed that the T2 relaxivity of SPIO cores were above 100 mM-1s-1, indicating 
that they were suitable to be used in the clinic.12 Preliminary experiments by Nagalla, using 
fluorophore-labeled, As33-conjugated silica-coated NPs, showed some evidence of cellular particle 





The goals of this study focus on quantifying cellular uptake of antibody-conjugated silica-
coated SPIO NPs in pancreatic carcinoma cells via bioimaging methods. MR imaging phantoms were 
designed and built to study live cells using MRI. A pH-dependent fluorophore was used to label 
antibodies to enable tracking of NPs during receptor-mediated endocytosis under a fluorescence 
microscope. The following sections present a theoretical and literature review of the use of SPIO NPs 
in MR imaging as well as the endocytosis of NPs. 
 
1.1 Fundamentals of Magnetic Resonance Imaging 
MRI relies on the theory of nuclear magnetic resonance (NMR) to create high contrast 
images indicative of the chemical environment and spatial composition of a material of interest. This 
overview will explore elements of nuclear magnetic resonance relevant to image formation, followed 
by a summary of using contrast agents in MRI to optimize image contrast.  
  
1.1.1 Theory of Magnetic Resonance14 
 The theory of magnetic resonance is dependent on the interaction between an applied 
magnetic field and a nucleus that possess spin. Spin is an intrinsic property of a nucleus. MR-active 
materials have a non-zero nuclear spin angular momentum (l), which results from an odd number of 
protons, neutrons, or both in the nucleus. Spin is dependent on atomic composition. The resonance 
absorption and relaxation properties of spin vary from nucleus to nucleus, and are affected by the 





Using the quantum mechanical model, a non-zero spin gives rise to non-degenerate spin 
energy states in the presence of a magnetic field, whose energies are quantized. The number of spin 
states is given by: 
  #  𝑆𝑝𝑖𝑛  𝑠𝑡𝑎𝑡𝑒𝑠 = 2 𝐼 + 1                                                                         [2] 
Almost all elements in the periodic table, with the exception of argon and cesium, have some NMR-
active isotope, but most are not abundant enough for detection.14a 1H is the most abundant isotope for 
hydrogen (99.9%). With its abundance in mobile water molecules in the body, 1H is an ideal atom for 
MRI. Since 𝐼 = 1/2 for protons, Equation [2] indicates that protons have two spin states, which are 
designated as +½ and -½. Energy spacing between two spin states depend on the gyromagnetic ratio 
(𝛾) of a nucleus, which is unique to the nucleus, as well as the strength of the external magnetic field 
(𝐵!) (Figure 2). The frequency associated with this energy difference between two states in known as 
the Larmor frequency (𝜔): 
  𝜔 =   𝛾𝐵!                                                                                                  [3] 
  This energy difference ∆𝐸 is used to produce an NMR signal by absorbing radiofrequency 
(RF) electromagnetic radiation at an appropriate resonance frequency  𝜈: 
  ∆𝐸   =   ℎ𝜈 =   𝛾 !!! 1 − 𝜎 𝐵!                                                                   [4] 








Although a rigorous mathematical description of spin requires quantum mechanical 
principles, a tangible explanation of how NMR-active materials interact with a magnetic field can be 
provided by the classical (Newtonian) model. A nucleus with spin has a magnetic dipole moment (𝜇), 
where the nucleus can be considered to gyrate about an axis at a constant velocity. Without 𝐵!, the 𝜇 
of nucleus precesses at the Larmor frequency and points in random directions, producing a net 
magnetization of zero. However, in the presence of  𝐵! , nuclear magnetic moments align in a 
direction with or against the direction of the external magnetic field (Figure 3A). Nuclei with 𝜇 
aligned with 𝐵! are in the lower energy spin state, while nuclei whose 𝜇 aligned against 𝐵! are in the 
higher energy spin state (Figure 2). In the presence of   𝐵!, although the net magnetization in the 
transverse plane is zero, the interaction (known as the Zeeman interaction) between the nuclei and   𝐵!  is 
constant and non-zero, with the component of the vector in the direction of   𝐵! remaining constant with 
time. Therefore, nuclei with magnetic moment in alignment with Bo are in the energetically favorable 
state in comparison to nuclei that aligned against  𝐵!. 
Although the two populations of nuclei are approximately equal, there is a slight excess of 
atoms (~ten in a million) in the energetically favored spin state, which creates a net magnetic 
moment (the sum of individual magnetic moments precessing out of phase) in the direction of  𝐵! at 
	  
Figure 2.14a Zeeman Effect. In the absence of an external magnetic field 𝑩𝒐, protons in the two spin states (up or 
down) have the same energy (Left). However, in the presence of 𝑩𝒐, protons with spin up (in alignment with 𝑩𝒐) 
are of lower energy than protons with spin down (opposing the direction of 𝑩𝒐). Moreover, there are more protons 







the Larmor frequency (Figure 3). The exact number of atoms in each spin state is governed by the 
Boltzmann distribution:  
   !!""#$!!"#$% = 𝑒!∆!!"                                                                                            [5] 
where 𝑁!""#$ and 𝑁!"#$%   are the number of nuclei in the upper and lower energy spin states, ∆𝐸 as 
the difference in energy between the spin states, 𝑘 as the Boltzmann constant, 𝑇 as temperature. This 
small excess of atoms in 𝑁!""#$ in comparison to 𝑁!"#$%  is critical to produce a non-zero signal. 
Since ΔE is very small in comparison to available thermal energy at room temperature, a very strong 
magnetic field is needed to create a detectable energy difference.  
 To produce and detect an NMR signal, the magnetic moment must be perturbed from its 
equilibrium state (the direction of  𝐵!) to the transverse plane, where signal is recorded. The 
application of RF pulse at Larmor frequency creates a small magnetic field precessing at that 
frequency. The net magnetic moments that were precessing out of phase around the direction of Bo 
now begin to precess in phase around the small magnetic field created by the RF pulse (Figure 4).  
	  
Figure 3.14a Each proton precesses about the direction of the external magnetic field  𝑩𝒐. A) If   𝑩𝒐is in the 
direction of the z-axis, the protons can be considered to be tracking two “cones”, one in the direction with or against 
the direction of   𝑩𝒐. B) Since there are more protons in the direction of   𝑩𝒐 than against, in a rotating frame of 
reference (where x and y can be of any value), there is a nonzero vector M of constant magnitude in the direction 





This causes the longitudinal magnetic moment to spiral into the transverse plane. In a rotating frame 
of reference, the longitudinal magnetic moment “flips” toward the transverse plane. The angle by 
which it flips is a function of the strength and duration of the RF pulse. The angle is known as “θ”; 
when θ=90o all the magnetic moments “flip” into the transverse plane.  
After the application of the RF pulse, the RF coil monitors the precession of the magnetic 
moment as it returns to equilibrium via T1 and T2 relaxation. Changes in the transverse magnetic 
field induce a current, which produces sinusoidal decaying signals known as free induction decays 
(FIDs). These signals are then Fourier transformed and spatially encoded into an MR image. More 
details of MR image formation are discussed in 1.1.3. 
 
1.1.2 T1 and T2 Relaxation 
 The two relaxation parameters, T1 and T2, characterize two separate and simultaneous 
processes by which the magnetic moment returns to equilibrium. In the quantum mechanics world, 
excited nuclei return to lower energy state. In the classical explanation, the nuclear magnetic 
	  
Figure 4.14b To produce and detect a signal, the net magnetic moment that was precessing out of phase in the 
direction of   𝑩𝒐 is “flipped” in to the transverse plane by the RF pulse. When the RF pulse is removed, the RF 





moments that precess in phase around the magnetic field become out of phase. T1, known as spin-
lattice relaxation, characterizes the recovery of the magnetic moment (𝑀!)  along the direction of   𝐵!, 
(Figure 5A). T1 is the time required for the recovery of 63% of 𝑀! to return to the direction of 𝑀!  (0). 
T2, known as spin-spin relaxation, on the other hand, measures the loss of phase of the magnetic 
moments in the transverse plane (𝑀!"). It is the time required to lose 63% of 𝑀!" from 𝑀!"(o) (Figure 
5B). Mathematically, T1 and T2 are time constants in the Bloch equations which characterize the two 
processes: 
  𝑀! 𝑡 =   𝑀! ! 1 − 𝑒 !!!                                                                     [6] 
  𝑀!" 𝑡 =   𝑀!" ! 𝑒 !!!                                                                        [7] 
Nevertheless, the rates associated with each exponential process are not the same; T2 decay occurs 
faster than T1 recovery.14a  
There is an additional relaxation time constant known as T2*, which includes the effects of 
spin-spin relaxation as well as the contribution of magnetic field inhomogeneity present in all 
samples (Figure 5C): 





Superparamagnetic materials are T2-contrast agents and have important effects on T2* 
relaxation. In the presence of an external magnetic field, they act as small magnets and cause local 
field inhomogeneity. SPIO NPs increase the rate of T2* relaxation of the water protons located close 





Figure 5.15 Relaxation Parameters. A) T1 relaxation time characterizes the recovery of the magnetic moment in the 
z-axis (parallel to the direction of the external magnetic field Bo. B) T2 relaxation time characterizes the dephasing of 
the magnetic moment in the x-y (transverse) plane perpendicular to Bo. C) T2* takes into account the inhomogeneity 





 1.1.3 Image Formation  
 There are many pulse sequences (protocols used to specify timing and strength of applied RF 
and magnetic field gradient pulses) that could be used to acquire MR images. All pulse sequences 
have two main parameters: Time to Repetition (TR) and Time to Echo (TE). TR is the time between 
the RF pulses that initiate a pulse sequence, whereas TE is the time between an excitation pulse and 
time at which a signal is collected from a FID. Unlike T1 and T2, which are intrinsic properties of the 
material1, TR and TE can be adjusted to achieve signal that have more or fewer contributions from 
T1 or T2 relaxation processes: 
  𝑠𝑖𝑔𝑛𝑎𝑙  𝑖𝑛𝑡𝑒𝑛𝑠𝑖𝑡𝑦   ∝ 𝑁 𝐻 𝑒!!"!!(1 − 𝑒!"!!)                                                    [9] 
where 𝑁 𝐻  is the number of mobile protons present. T1-weighted images generally have a short TE 
and a short TR to maximize the effects of longitudinal relaxation.14c Comparatively, T2-weighted 
images tend to have longer TE and TR, to capture the effects of transverse relaxation.14c    
Since SPIOs have little effect on T1 relaxation, the following discussion will focus on T2-
weighted image formation. To produce an MR image, proton frequencies are localized to different 
regions of space by applying gradients. Gradients are small linear perturbation superimposed on Bo, 
so that the exact magnetic field, Bi, is linearly dependent on the location of protons inside the magnet. 
Three gradients are used to specify spatial information in three dimensions (3D), one in each axis. 
Each physical gradient has one or more of the functions for obtaining an image: slice selection, phase 
encoding, and frequency encoding. These functional gradients are applied sequentially (Figure 6). To 
begin, a gradient coil localizes RF excitation to a region of space using a slice-selecting gradient 
along one of three dimensional axes (x, y, and z). This RF pulse has a narrow range of frequencies, 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
1 T1 and T2 relaxation times are intrinsic properties of a material. However, in the presence of contrast agents, T1 





which allow for the excitation of a “slice” of tissue with the matching Larmor frequency. Along the 
two remaining axes, a phase-encoding gradient is applied after the RF pulse, while a frequency-
encoding gradient is applied during readout and the formation of the echo. 
 
The simplest pulse sequence is a Spin Echo, where a 90o excitation RF pulse is applied to flip 
the magnetic moment into the transverse plane (Figures 6 and 7). At time τ, a 180o pulse inverts the 
magnetic moment and refocuses the dephasing transverse magnetic moment. Since T2 relaxation is 
an intrinsic property, only signal decay due to spin-spin interactions are refocused. The point of 
maximum rephrasing occurs at 2τ. This point of rephrasing is known as an echo. The signal is 
measured at 2τ, known as TE, to form T2-weghted images. The decay function of the signal can be 
fit to obtain the time constant T2: 
                   𝑆𝐼!!   = 𝑠!(𝑒!!"!!)                                                                                 [11] 
              ln 𝑆𝐼!! =   − !"!! + ln 𝑠!   
	  
Figure 6.14a Timing of gradients in a standard multi-echo spin-echo pulse sequence. The slice-selecting gradient 
is applied during the application of the radiofrequency (RF). The phase encoding gradient is applied after the RF 





              ln 𝑆𝐼!! = 1 − !!! 𝑇𝐸 + ln  (𝑠!)  
The final step is to Fourier transform the signal intensity values from the time to the frequency 
domain for image formation. 
 
1.1.4 SPIO as MRI contrast agents 
Most iron oxides are ferromagnetic. NPs with diameter greater than 10 nm contain multiple 
magnetic domains separated by domain walls (Figure 8). These domains align with or against the 
direction of Bo, and retain some residual magnetization even after Bo is removed. For NPs smaller 
than 10 nm in diameter, it is less energetically favorable to form domain walls. In other words, it 
costs more energy to create a domain wall than to support a single domain.16 As a result, these NPs 
smaller than 10 nm in diameter form a domain on their own, and are known as superparamagnetic. 
SPIO NPs align their domains with or against the direction of Bo in the presence of an external 
	  
Figure 7. Radiofrequency component of Spin Echo Pulse Sequence (Adapted from Kolodny, 2013).14b Multiple 
180o pulses follow a 90o pulse to refocus the transverse magnetic moment in the transverse plane, forming an echo. 





magnetic field. When Bo is removed, the magnetic domains of SPIO NPs revert completely back to 
random directions, and have no dependence on how many times the NPs had been exposed to a Bo. 
In the absence of Bo, SPIO are nonmagnetic. 
When SPIO NPs are inserted into an area of interest with mobile water protons, they act as 
bar magnets in the presence of an external magnetic field. SPIO NPs create their own local magnetic 
field, which increases local field inhomogeneity. This in turn results in the increase of the rate by 
which the transverse magnetic moment of the nearby water protons dephases in an area. The 
shortening T2* relaxation time of water protons decreases signal, and causes the area to darken. Thus, 
a contrast agent works by increasing the contrast level of the area of interest to beyond its intrinsic 
level of contrast. The darkening of image is concentration dependent. The more iron oxides that are 
present in the area of interest, the darker the image. 
The quality of contrast that MR contrast agents provide is quantified by T2 molar relaxivity, 
r2, which is dependent on concentration of the contrast agent and the decrease in T2. By collecting 
FIDs at different TEs and determining T2, r2 of SPIO NPs can be calculated as follows: 
 !!! =    𝑟![𝐹𝑒!!/!!]                                                                                            [12] 
	  
Figure 8.17 Ferromagnetic nanoparticles (NP) contain multiple domains while each superparamagnetic NP is a 






There are many advantages of SPIOs over other-metal based NPs, as iron may be easily 
integrated into tissue physiology, depending on its ability to interact with a cell membrane and enter 
the cell. On inside a cell, iron oxide can be metabolized, stored and transported through tissue via 
ferritin, transferritin, and homosiderin.17 The resultant iron can be incorporated into the iron pool for 
other uses. In fact, rats subjected to 100 mg Fe2+/3+ per kg had no identifiable side effects, although 
effective contrast can be achieved with a much lower dosage.18  
 
1.2 Cellular Uptake of SPIO NPs 
 In order for SPIO NPs to perform their functions in drug delivery, they must first enter the 
cell. The phospholipid bilayer of the cell membrane controls what goes in and out of a cell. While 
some molecules, such as water, can enter or leave the cell membrane freely, small polar or charged 
extracellular material (i.e. amino acids and metal ions) use protein or ion channels with the 
expenditure of energy to enter cells, while macromolecules as well as NPs, depend on endocytosis 
(see below). Cell membrane properties, such as surface charge, fluidity, receptor type, rate of 
receptor production, and characteristics of NPs, including their size, shape, surface charge, coating, 
and conjugated ligand, all affect how particles interact with a cell. The interaction between 










1.2. 1 Pathways of Vesicle Transport  
Although there are many transport pathways in the cell (as shown in Figure 9), there are three 
main pathways used for NPs to enter a cell: pinocytosis, caveolae-dependent endocytosis (CDE), and 
clathrin-mediated endocytosis (CME). Pinocytosis is the predominant method of uptake of large NPs 
and microparticles. It is the method by which a cell engulfs extracellular contents and fluid, and can 
occur without direct interaction between NPs and the cell membrane.20 CDE, on the other hand, 
forms vesicles between 50–1000 nm via cell membrane invaginations for the uptake of anionic NPs 
and NPs >500 nm in diameter.21 Vesicles formed from CDE enclose sphingolipids and cholesterol, 
and bind to associated proteins to form microdomains that contain cationic lipids.22 It is the 
predominant method of particle cellular uptake in endothelial and muscle cells.20b Another well-
studied form of endocytosis is clathrin-mediated endocytosis (CME), which occurs in all nucleated 
	  
Figure 9.19  Transport Pathways in Cells. Secretory, lysosomal/vacuolar, and endocytic pathways are the many 
methods materials outside of the cell are sorted and packaged upon entering the cell. Arrows indicate the direction of 
transport. The function of COPII (coatamer proteins II, blue) in endoplasmic reticulum (ER) export and clathrin 
(orange) in membrane associated endocytosis are known with certainty. The exact roles of COPI (coataner proteins I, 
red) at the ER-Golgi intermediate compartment (ERGIC), and clathrin in the trans-Golgi network are unclear, as the 
process of transport through the Golgi stack remains a mystery. There exist coating proteins other than clathrin that 





cells in vertebrates. Clathrin is a protein with three light and three heavy chains that form a three-
legged structure called triskelion. Along with clathrin-associated protein components with different 
functions, known as “assembly peptides”, clathrin assembles into complexes of hexagons and 
pentagons that form coated pits on the cytoplasmic surface. Clathrin-coated vesicles are around ~100 
nm in diameter and are the primary vesicles involved in receptor-mediated endocytosis, which could 
be used for targeting specific cells. 22b, 23  
 
 1.2.2 Receptor-mediated Endocytosis 
 Whereas non-specific NP-cell interactions are induced by cargo of specific sizes, which 
could be a few large NPs or a cluster of small NPs, specific NP-cell interactions depend on the 
binding between a receptor and its ligand. The internalization of ligand-conjugated NPs also allows 
the targeting of NPs to specific cells.23b, 23c Some membrane proteins, such as low-density 
lipoproteins (LDL), have receptors that are constitutively concentrated in clathrin-coated pits, where 
vesicles form.  These pits can contain as high as 70% LDL receptors, and all pits together can take up 
to 0.4 to 3.8% of cell surface area, with an average of 2%.24 Due to the amount of receptor at the pits, 
materials enter cells rapidly via receptor-medicated endocytosis (10–50 %/min). Other receptors 
become concentrated in clathrin pits upon ligand binding. Specific peptide sequences, known as 
“internalization motifs,” act as the entrance tickets for extracellular materials and specify where these 
materials will locate in the cell. For example, the same amino acid sequence could be used to get 
through cell membrane and target the trans-Golgi network, though the precise mechanism remains 
unknown.25 Moreover, it is unclear whether coated pits form before or after receptor recruitment. 
Nevertheless, there are some general patterns in “internalization motifs” despite an absence of a 





stretch of acidic residues and aromatic residues, especially tyrosine, though there are leucine and 
lysine-based cytoplasmic targeting sequences.19  
 For ligand-conjugated NPs to enter targeted cells, they must be located at receptor-rich areas 
on the cell membrane. Initially, NPs must adhere to the cell surface. After overcoming resistive 
forces (including electrostatic, Van der Waals forces, and more), the remaining thermodynamic 
energy must counteract the elastic recoil force of the cell membrane to allow for membrane wrapping 
and forming a vesicle to engulf the NP at the site of adhesion.27 The precise mechanism of vesicle 
budding and fusion is explained by the vesicular transport hypothesis.  
  
 1.2.3 Particle-Cell Interactions during Receptor-Mediated Endocytosis 
There are many factors that affect NP-cell interactions during receptor-mediated endocytosis. 
Typically, clathrin coats generate buds that are 50–250 nm in diameter, which explains why the 
upper limit diameter of NPs entering the cell via this pathway is 200 nm.20b, 28 For most clinical 
purposes, the NPs used are above 100 nm in size.29 However, studies have shown that NPs with a 
diameter smaller than 100 nm are generally more readily taken up into the cell than NPs larger than 
100 nm, with an optimal diameter of 50 nm.30 In fact, silane-PEG coated magnetic iron oxide NPs 
with a diameter of 40 nm showed greater accumulation in murine tumors than those that were half 
the diameter.31 It is likely NPs smaller than 25 nm are too small to trigger CME, and a larger number 
of NPs are required to initiate internalization.20b  
 The cell type with which NPs interact can interfere with the ideal diameter for NP uptake. 
While embryonic fibroblasts preferentially take up gold NPs around 25 nm in diameter, tumor cell 





dependence on different vesicular transport pathways. For example, macropinocytosis is absent in 
brain capillary endothelial cells.33     
 The shape of NPs also matters. In some studies, rod-shaped gold NPs were found to enter 
cells more slowly than spherical ones, perhaps due to kinetics as it takes longer for the cell 
membrane to wrap around a rod.34 However, in studies using different materials, the highest 
internalization rate of hydrogel particles in HeLa cells was for rods with an aspect ratio (a value 
obtained from dividing the length of the major axis by the width of the minor axis) of three, rather 
than spherical ones.35 Moreover, molecular dynamics simulations of uptake of ligand-conjugated NPs 
reported higher efficiency for rod-shaped than spherical NPs.36 On the other hand, sharp edges on 
NPs tend to suppress endocytosis, as they may interfere with membrane wrapping.36 
Surface characteristics and charge can be tuned to improve internalization of NPs. Cellular 
uptake of NPs could be improved by the presence of a cell penetration peptide (CPP), which induces 
local clotting at the cell membrane after penetration that served as new binding sites.37 Cationic NPs, 
even in the absence of a CPP, can induce CME by interacting with the anionic head groups of the 
phospholipids that make up the cell membrane.38 Membrane charge, although different between 
monolayer cell culture and in vivo, can affect the ability of NPs to interact with the cell membrane 
surface.  Moreover, NPs coated with dichain cationic emulsifiers (DMAB) showed higher cellular 
uptake than single-chain cetyltrimethylammonium bromide (CTAB)- or dodecyltrimethylammonium 
bromide (DTAB)-modified ones.20b Ionic interactions between lipids and cationic NPs allow for 
rapid uptake, which provides a promising platform for gene delivery as RNAi mandates the 
cytoplasmic targeting.39 Anionic NPs, unlike cationic ones, rely on adsorptive endocytosis. Bare and 
silica (SiO2)-coated iron oxide NPs have hydroxyl groups on the surface, making them slightly 
negatively charged. SiO2-coated iron oxide NPs of different sizes have been used to label human 





cellular uptake, surface modifications can be used to achieve other functions. Cobalt ferrite magnetic 
NPs with a SiO2 shell-core modified with fluorescein isothiocyanate (FITC) and rhodamine B 
isothiocyante (RITC) dyes enable dual-modular imaging via optical and MR imaging.40 Other 
protein-based surfactants, such as transferrin, demonstrated increased internalization, 
biocompatibility, and most importantly, greater inhibition of tumor growth in prostate cancer cells 
when conjugated to therapeutic-based NPs.20b With the help of surfactants, NPs can even cross the 
blood brain barrier (BBB). PEGylated Fe3O4 NPs covalently conjugated to lactoferin (Lf), which 
binds to Lf receptors present on cerebral endothelia cells, were show to successfully move NPs into 
the brain via receptor-mediated transcytosis.41  
 To enable active targeting of NPs to specific cells, antibodies, especially monoclonal 
antibodies (mAb), provide the potential to concentrate cytotoxic agents in tumor cells, while sparing 
healthy tissue. SPIO NPs modified with mAb (muj591) have been shown to target prostate-specific 
membrane antigen (PSMA) and significantly decrease T2 in PSMA-positive cells.42 There are, 
nevertheless, several disadvantages of using mAb, including premature drug release or antigen 
shedding, as the presence of serum proteins and enzymes, especially those released by our immune 
system, may bind and disrupt the integrity of mAb on the NP.43 When drug and linker are both 
hydrophobic, mAb-conjugated NPs could also suffer from aggregation which results in reduced 
circulation time.44 As a result, the mAb used for targeting purposes must be chosen carefully to 
achieve the ideal targeting efficiency. 
 To improve circulation time of NPs, to thrive in the protein-protein competitions, and to 
avoid the defensive mechanism provided by the reticuloendothelial system (RES), the most common 
strategy is to add a particle coating. While albumin can minimize non-specific interactions between 
NPs and other proteins in the bloodstream, polyethylene glycol (PEG) is often the molecule of choice 





chain length and surface density, where an initial concentration of 10.6 mol% of PEG could provide 
a sufficient time window to reach the target.3 Similar to mAb, the chain length and structure of PEG 
must be optimized, as they could interfere with cellular targeting.45  
 
 1.2.4 Intracellular Localization of NPs 
Once entering the cell, NPs are kept in endosomal vesicles (with an internal pH 6.5) which 
mature into late endosomes before fusing with lysosomes (pH 4-5).46 The acidic contents as well as 
the presence of digestive enzymes can result in the digestion of NPs. Alternatively, NPs that escape 
digestion maybe recycled back to the cell surface by trafficking endosomes. Some nanomaterials, 
especially cationic and basic NPs, are capable of escaping the endosome. A theory known as the 
“proton sponge effect”, where phase transitions of pH-dependent lipids or peptides result in osmotic 
swelling of vesicles and disruption of the endosomal membrane, thereby allowing NPs to escape, is 
used to explain such phenomena.27, 33, 47 Endosomal escape is necessary for NPs to be delivered to 
various locations in the cell other than the lysosome, including the cytoplasm (i.e. small interfering 
RNA, siRNA), the nucleus (for delivery of DNA or chelating agents), and the mitochondria 
(antioxidants or mitochondrial DNA). Some nanomaterials, such as some carbon nanotubes, can 
penetrate vesicular or cell membrane to enter the cytoplasm even in the absence of targeting ligand.48 
However, for BNCT, NP escape from the endosome is not necessary. Although the destination of our 
NPs in the cell remains unclear, a pH-dependent fluorophore activated only at low pH is used to track 
the SPIO NPs optically as they enter the endosomal pathway. 
The interactions between many aspects of the cell and the NP dictate whether and how NPs 





NP must be optimized to achieve appropriate targeting efficiency of NPs for efficient drug delivery 





















2 Materials and Methods 
 
2. 1. Synthesis of Silica-coated Iron Oxide Nanoparticles 
 Silica-coated iron oxide nanoparticles were synthesized using a reverse micro-emulsion 
method adapted from Narita et al. and thesis work by J. Rana.49,7 Cyclohexane (J.T. Baker, >99%) 
and Igepal©CO-520 (Sigma Aldrich) were mechanically mixed on a magnetic stir plate (Thermolyne 
Cimarec) for 5-10 minutes and the magnetic stir bar was then removed. An aliquot of aqueous EMG 
304® Ferrofluid (Ferrotec) was weighed and added to the cyclohexane-Igepal mixture with 
sonication. The final cyclohexane-Igepal-Ferrotec solution was sonicated for 5 minutes to establish a 
reverse micro-emulsion phase, before NH4OH (Sigma Aldrich 28% w/v) was added to increase the 
pH of the solution to 11.0±1.0. The pH was measured using universal pH indicator paper (Precision 
Labs, Inc.).  This solution was left on a wrist-action shaker (Burell Scientific) for one hour. Next, 
tetraethyl orthosilicate (TEOS, Sigma Aldrich, 99.9%) and PEG-silane (Polymer Source, Trimethoxy 
propyl-terminated PEG methyl ether, 420 MW) were added to the sonicated NH4OH micro-emulsion 
mixture. The final solution was left on a wrist-action shaker for 1 to 46 hours before the reaction was 
terminated by the addition of an equal volume of abs. EtOH (VWR International).  The terminated 
reaction mixture was left on the shaker to continue mixing for one hour, before the sample was 
placed beside a neodymium magnet (Applied Magnets, N50, 32+ lbs pull force) for collection. The 
supernatant was decanted and the products (dark brown pellets) were washed three times with abs. 
EtOH before re-suspension in 18.3 Ω H2O (nanopure water, nH2O). Silica-coated NP solutions were 
then filtered through a 0.45 µm cellulose acetate membrane (VWR International) to remove larger 






2.2 Transmission Electron Microscopy (TEM) 
 
 Size and morphology of nanoparticles were examined under a JEOL 1200EX transmission 
electron microscope (80-100 KV accelerating voltage) at the Department of Cell Biology, Harvard 
Medical School. Samples were prepared by suspending a formvar 400 mesh CU grid (Ladd Research) 
upside-down in 1-2 drops of sonicated nanoparticle solution for 15 minutes. The excess liquid on the 
grids was removed using Kimberly-Clark® Kimwipes™ and the grids were left to dry in air for at 
least 24 hours. TEM images were taken between 25000 and 64000 x magnification. The nanoparticle 
sizes were determined using an AMT 2k charged-coupled device (CCD) camera system. The CCD 
detects the movement of electrical charge from the electrons scattered from the sample and moves 
this charge to an area where the charge can be converted into a digital value in order to create an 
image, where the size of the sample is calculated.  
 
2.3 Dynamic Light Scattering (DLS) 
 
 Particle size distributions of bare and coated iron oxide nanoparticles were measured using 
dynamic light scattering (Malvern Nano-ZS), when possible. Samples suspended in 18.3 Ω H2O were 
sonicated for 1-2 minute(s) before dilution to a concentration between 6-12 µM. The diluted 
Table 1. Typical amounts of reagents used in the synthesis of PEGylated silica-coated iron oxide nanoparticles. 
Reagent Amount 
Cyclohexane 10 mL 
Igepal CO-520 0.5 mL 
Ferrotec EMG 304® 0.006 – 0.06 g 
NH4OH (28% w/v) 875 µL 
TEOS (99.9%)                      5 µL 






solutions were filtered using a syringe filter with a 0.45 µm cellulose acetate membrane (VWR 
International) to remove dusts and larger aggregates. Size measurements and monodispersity data 
were collected using the standard operation files SiO2 in water.sop and FexOy.sop (173º backscatter 
measurement, 120 s equilibrium time, RI=2.940, Abs=0.05 in water at 25 ºC) and averaged over 
three trials of 12 to 16 readings each.  
 
2.4 Fourier-Transform Infrared Spectroscopy (FT-IR) 
 
 IR spectra of the bare and functionalized nanoparticles were obtained using a Perkin-Elmer 
Spectrum One FT-IR spectrometer with a universal ATR sampling accessory (scanning range: 650-
4000 cm-1; number of scans: 64-256; resolution: 2.00 cm-1) to independently confirm the presence of 
silica coating. Stock FexOy NPs (~750 µl) suspended in abs. EtOH were centrifuged at 13000 rpm for 
five minutes. Supernatant was decanted until only 20-30 µL of liquid was left inside the eppendorf 
tube. Using a glass pipette, the leftover supernatant was mixed with the NP pellet to make 
concentrated NP slurry. A drop of the resulting viscous NP solution was pipetted over the ATR 
crystal and left to air dry until the EtOH completely evaporated (5-10 minutes).  IR spectra were 
taken from the solid NP remnants using air as background scan (adapted from H. Yayla thesis). 50   
 
2.5 Antibody Conjugation to NP 
 
 Monoclonal antibody that targeted GA33 was conjugated onto NP surface using methods 
adapted from thesis work by R. Nagalla (Wellesley College, '14).51  
  
2. 5.1 Creation of the ProteinA/G-Mal-PEG-Silane Linker  
 
 Samples of Protein A/G (ProSpec, PRO-646) reconstituted to 1 mg/L in sterile PBS were 





proteinA/G were then purified using a 7k MWCO desalting spin column (ZebaTM Thermo Scientific 
89892) according to manufacturer's instructions, and coupled to 5kDa Maleimide-PEG-silane 
overnight at 4 oC in a 1:10 (protein A/G to PEG) molar ratio on an orbital shaker (Fisher Scientific), 
to create a linker-antibody complex. This complex was purified with a second a 7k MWCO desalting 
column (ZebaTM Thermo Scientific 89892).  
 
2.5.2 Antibody Conjugation to NP via Linker 
 Immediately after purification, the protein A/G-Mal-PEG-silane complexes were tethered to 
the silica surface of SiO2@NP in linker excess at 4 oC on a orbital shaker overnight. Linker-
conjugated silica-coated NPs were then collected by a magnet and washed three times with sterile 
PBS. The protein A/G@Mal-PEG-silane@SiO2@NPs were then analyzed for protein absorbance at 
280 nm using a spectrophotometer (NanoDrop 2000, Thermo Scientific) to verify the presence of 
protein A/G on the NPs and the absence of proteins in the supernatant.  
 Upon confirmation of linker attachment to the NP surface, monoclonal antibody As33 (mAb 
provided by Prof. Andrew Webb, Wellesley College) tagged with pHrodo-Green Fluorophore (Life 
Technologies) was added to the protein A/G@mal-PEG-silane@SiO2@NPs in antibody excess. The 
mixture was left to shake on an orbital shaker for 24 hrs at 4 oC, for protein A/G to bind with the Fc 
portion of mAb As33. The presence of As33 was indirectly verified via the presence of green 
fluorescence on the NP pellet (not in supernatant) under a fluorescence dissecting microscope (Leica, 
M165FC) using a green fluorescent protein (GFP) filter and an Enzyme-Linked ImmunoSorbent 








2.6 Enzyme-Linked ImmunoSorbent Assay (ELISA) for Antibody Quantification 
 A modified method based on an Enzyme-Linked ImmunoSorbent Assay (ELISA) protocol 
developed by Harini Natarajan'15 was used to quantify the amount of As33 present on the surface of 
the silica-coated NPs.  Protein A (1 µg/mL, Life Technologies) in sterile 1X PBS (American 
Bioanalytical AB11108) was used to coat seven out of eight rows of a 96-well polystyrene assay 
plate overnight at 4 oC. Protein A acted as the binding partner to the antibodies on the plate (Figure 
10). The last row of wells was coated with PBS to provide information about background absorbance 
levels. The plate was washed three times with 1X TBS (Sigma Aldrich T5912) with 0.05% TWEEN 
20 (1X TBST, Sigma Aldrich), and blocked with 1X TBST with 2% dried milk (Bio-Rad 1706404 ) 
	  
Figure 10. Steps of well treatment in a typical Enzyme-Linked ImmunoSorbent Assay (ELISA) prior to 
secondary antibody addition. Top: Addition of Protein A (1 µg/mL) in the first seven rows, with PBS as control 
in Row 8. Bottom: Addition of As33 and NP serial dilutions were added in triplicates in Rows 1-6. Serial dilutions 







for one hour at room temperature. Twelve serial dilutions of nanoparticles and mAb As33 (1 µg/mL) 
were prepared in 1X TBST with 0.1% BSA (Santa Cruz Biotech Sc2323). NP and mAb As33 
dilutions were then added to the plate in triplicates. In the seventh row, 1X TBST with 0.1% BSA 
was added in the absence of NPs or As33 to ensure that the secondary antibody did not cross-react 
with protein A. The solutions were then incubated at room temperature for one hour and washed 
three times with 1X TBST before exposure to a secondary antibody, a goat anti-mouse antigen-
binding fragment (Fab, Jackson ImmunoResearch 115-036-072) for As33 conjugated with 
horseradish peroxidase (in 1X TBST with 0.1% BSA) for one hour at room temperature. After 
incubation, the plate was washed three times with 1X TBST to remove weakly bound proteins. The 
3,3',5,5'-tetramethylbenzidine (TMB, Thermo Scientific 34028), a horseradish peroxidase (HRP) 
substrate, is then added as a staining method, developing a blue color in the solution with HRP 
activity to indicate the binding of secondary antibody to As33. The reaction was stopped using 2M 
H2SO4 (Thermo Scientific, ACS grade) and absorbance intensity at 450 nm read with a SpectraMax® 
M3 microplate reader (Molecular Devices). A standard curve of absorbance vs. As33 concentration 
was created using Beer's Law (A=ɛcl) and the concentration of As33 in the NP sample was 
calculated based on this standard curve.  
 
2.7 Uptake of Particles by Cells 
 
2.7.1 Cell Culture 
 
 CAPAN-2 and BxPC-3 human primary pancreatic adenocarcinoma cell lines were provided 
by Prof. Andrew Webb (Wellesley College). For 2D cell culture, tumor cells were grown in RPMI 





 For 3D cell culture, tumor cells were first grown in T-150 culture flasks until ~70% confluent, 
before being scraped from the flask and washed twice with PBS. After washing, cells were 
resuspended in RPMI media without phenol red, antibiotics, fetal bovine serum, but with 0.5% BSA 
for BxPC3. For CAPAN-2 cells, 2% methylcellulose was included in the previously mentioned 
media solution to assist with spheroid formation (method based on a protocol developed by Karina 
Verma '14). 200,000 to 250,000 cells were seeded in each well of the 96-Well Hanging Drop Plate 
(3D Biomatrix) and incubated at 37 °C and 5% CO2.  Cell counts were performed with a 
hemocytometer. In the case to create a standard curve of cell counts, both a hemocytometer and an 
automated cell counter (Moxi Z TM, ORFLO) were used for cell counting.  
 
2.7.2 Particle Exposure 
  
 As33-conjugated silica-coated NPs or silica-coated NPs at 2.45 nM Fe2+/3+ concentration 
were subjected to CAPAN-2 and BxPC-3 cells at three time points of tumor spheroid formation: 
before formation (immediately after seeding), beginning of formation (5 hrs), after formation (36 hrs) 
for two hours. An excess of NP cores, at approximately 0.04 mM, was also used as control. Post NP 
exposure, tumor spheroids were transferred to a 96-well polystyrene assay plate, before being 
collected into larger cell pellet in a PCR tube. The spheroids were washed twice with PBS before 
imaging via MRI.  
 
2.8 Inductively Coupled Plasma Optical Emission Spectroscopy (ICP-OES) 
 
 The concentration of Fe2+/3+ and Mg2+ ions were determined using an Optima 7000 DV ICP-
OES spectrometer and an analysis protocol adapted from Oca-Cassio et al.52 An aliquot (1-2 mL) of 
filtered, diluted FexOy NP solution (bare or functionalized) was acid digested with 35% w/w high-





crystal lattice, releasing free-floating Fe2+/3+ into the solution. Similarly, a volume excess of 69% 
high-purity HNO3 (OmniTrace Ultra) was used to digest cell pellets, after removal of supernatant, for 
a minimum of 48 hours to release cellular Mg2+ ions into solution. A temporary increase in solution 
temperature and a color change from rust brown to clear liquid were indicators of progress in the 
digestion of FexOy NPs. A change of clear to light yellow in the acid solution were indicators of 
cellular digestion. The acid-digested samples were then diluted with nH2O to create 5-10 mL of 2% 
HNO3 w/w solution of acid-digested NPs or cell pellets in 15 mL conical centrifuge tubes that were 
previously soaked in 2% HNO3 overnight. Atomic emission intensities of known concentrations (40 
ppm, 4 ppm, 0.4 ppm, 0.04 ppm, and 0.004 ppm) of Fe2+/3+ standard solutions were taken at λem= 
238.204 nm. For magnesium, Mg2+ standard solutions (1 ppm, 0.1 ppm, 0.05 ppm, 0.01 ppm, and 
0.001 ppm) were read at 279.077 nm or 283.204 nm. These values were plotted as a function of 
[Fe2+/3+] or [Mg2+] to create standard curves. Sample [Fe+2/+3] or [Mg2+] were calculated by 
substituting sample signal intensity values collected at λem= 238.204 nm, 279.077 nm, or 283.204 nm 
into the standard curves. Since iron and magnesium standards were analyzed before each batch of 
samples, a new standard curve was calculated for each batch of samples. A sample standard curve for 













Figure 11. Intensity vs. concentration standard curve of Fe in the iron oxide nanoparticles used in ICP-OES 
determination of iron concentration in the nanoparticles samples. 
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2.9 MRI Phantom Preparations and Relaxivity Studies 
2.9.1 Nanoparticle Characterization  
 FexOy NP samples in nH2O were prepared by pipetting an equal volume (0.5-1 mL) of 3 
serial dilutions (typically 0.03-0.3 mM) of FexOy NP samples in nH2O into individual 3 mm OD 
NMR tubes (Wilmad). Sample NMR tubes were then put into a customized, reusable phantom holder 
designed by Stephanie Huang ’12 (Figure 12). A typical MR image of the phantom is shown on the 
right: 
To obtain T2 relaxation times of the NP samples for molar relaxivity calculations, MR 
images (400 MHz Bruker Avance NMR spectrometer, 9.4 T, vertical bore, 2.4 G/cm/A gradient 
strength) of the iron oxide NPs samples were acquired with Bruker Paravision 4.0 MSME-T2 Map 
pulse sequence (TR=3062 s, TE=10, 20, 30,…, 600 ms, 60 echoes, avg=1, 4x4 cm FOV, 128x128 
matrix). By fitting an exponential decay curve to a plot of TE vs. signal intensity using the Image 
Sequence Analysis (ISA) tool in Paravision for each iron oxide NP concentration as outlined in the 
Appendix of Yayla’s thesis, T2 relaxation times of each sample were determined.50 The slope of the 
 
Figure 12.A) Customized reusable phantom designed by Stephanie Huang '12. The phantom can hold up to 






line of best fit between 1/T2 and [Fe2+/3+] (determined by ICP-OES as outlined in Section 2.8) is 
known as the molar relaxivity of the NPs according to the following equation: 
𝑟! = 𝑅!𝐹𝑒 ,𝑤ℎ𝑒𝑟𝑒  𝑅! = 1𝑇2 
Statistical tests of molar relaxivity between slices and various syntheses were computed using SPSS 
22.0. 
 
2.9.2 MRI of Cell Pellets 
 Three customized designs of MRI phantom were built for imaging tumor cell pellets using 
MRI (Fig.13). Designs A and B were built for containing individual wells from a 96-well plate. 
	  
Figure 13. Three customized phantom designs were built by Larry Knowles (Wellesley College) for 
imaging tumor cell pellets. Design A) contained a two layers with wells that have a diameter of 6.86 mm 
(comparable with wells in 96 well plates, while Design B) contains a single layer. Design C) was created to hold 
0.2 mL PCR tubes. A fully assembled phantom with Design C) is shown in D). E) is a comparison between the 





Design C was built for containing PCR tubes. T2 relaxation times of cell and PBS samples were 
determined using the Image Sequence Analysis (ISA) tool in Paravision 4.0 following directions 
outlined in the Appendix of a thesis by H. Yayla.50 One-Way ANOVA of the T2 relaxation times of 




















3 Results and Discussion 
3.1 Synthesizing Silica-Coated Particles  
The diameters of individual Ferrotec© NPs before and after silica-coating formation were 
measured by transmission electron microscopy (TEM). Darker regions of the micrographs represent 
NP cores, whereas lighter regions represent silica coating (Figure 14). Although Ferrotec© FexOy 
cores were advertised as 10 nm spheres, they were 15±2 nm (n=20) in size and not spherical in shape 
(Figure 14A). Silica-coated NPs were 23±4 nm in diameter, with some aggregation (Figure 14B). By 
approximating the core size as 15 nm, the thicknesses of the silica-coating on the NPs were 
 
Figure 14. Transmission electron micrographs (TEMs) of A) uncoated iron oxide cores, 15±2 nm (n=26) and B) 
silica-coated NPs in 2 hr, 23±4 nm (n=22). Images obtained using copper TEM grids coated with Formvar.12  Blue 






approximately 4 nm.  
The coating of FexOy NPs was further analyzed using FT-IR spectroscopy. The presence of 
silica on FexOy NPs was confirmed via the presence of a peak around 1080 cm-1 (Si-O stretch), as the 
bare FexOy NPs showed a flat region in spectrum (Figure 15). Uncoated FexOy NPs showed two 
small fluctuations in the CH-sp3 stretch region, which may be due to a coating of oleic acid on the 
particle surface. However, this fluctuation disappeared when the FexOy NPs were coated with silica 
and only a peak indicating the presence of Si-O bonds remained.  
 
3.2 Antibody Conjugation and Quantification 
The presence of As33 on antibody-conjugated SiO2@NPs was confirmed and quantified 
using an enzyme-linked immmunosorbent assay (ELISA) (Figure 16). Absorbance of the antibody 
 
Figure 15. FT-IR spectra of bare Ferrotec© NPs (top), the silica-precursor tetraethylortho silicate (TEOS) 
(middle), and silica-coated NPs (bottom). Silica-coated NPs has a peak in the characteristic Si-O stretch region 






Figure 17. Color change observed in the ELISA plate for quantifying the number of antibody per 
nanoparticles (NPs) (See Figure 10). Serial dilutions (with most concentrated solution in Well 1) of As33 
antibody standards in triplicates are in Rows A-C. Serial dilutions (with most concentrated solution in Well 1) of 
As33@silica@NPs in triplicates (Rows D-F) displayed a color change to yellow, indicating the presence of 
secondary F’ab binding to the NPs. To ensure that the secondary F’ab did not bind nonspecifically to the plate, 
row G was exposed to TBST buffer with 0.1% BSA (no As33). To quantify background absorbance and to 
confirm that NPs did not bind non-specifically to the plate, row H did not have any protein A but was exposed to 
the same serial dilutions of As33@silica@NP as Rows A-C. 
	  
Figure 16.  Absorbance values less than 1 from serial dilutions of As33 collected at 450 nm were used to produce 
a standard curve. This standard curve was used to quantify the concentration of antibody presence in 
As33@SiO2@NPs dilutions in an ELISA using As33@SiO2@NPs dilutions that had an absorbance between 0.1 
and 0.8 (n=3). 
y = 0.0106x + 0.0717 















standard at 450 nm was used to create a standard curve, from which As33 concentrations in the NP 





As33@SiO2@NP sample used in the ELISA and did not have above background absorbance at 
λ=450 nm. The lack of absorbance from the flurophore conjugated to As33 suggested that the 
fluorophore on As33 did not affect sample absorbance at this concentration, although work by 
Nagalla suggested that 20 µM pHrodo fluorophore had a small absorbance at 450 nm.13  
 ELISA results indicated that there was an average of 0.0043 nmol/mL of As33 in the stock 
As33@SiO2@NP solution (N=3). Assuming that each antibody is approximately 150 kDa, there 
were 2.57x 1012 antibodies per 1.64 x 1012 NP, which was 1.6 antibodies to each NP two months after 
the conjugation reaction took place, suggesting stability of the antibody conjugation. DLS 
measurements showed that As33@SiO2@NPs have a median hydrodynamic radius of 109±7 nm 
(N=26).  With an average polydispersity index value (PDI) of 0.421, the nanoparticles had a range of 
sizes after antibody conjugation (Figure 18). TEM of the nanoparticles confirmed this finding (Figure 
19). Moreover, antibody-conjugated NPs seemed to be in found either in clump of 110±20 nm or as 
singletons at approximately 30 nm each, indicating a degree of aggregation in these samples (Figure 
19A). Regular spacing between the NPs suggested the presence of a PEG linker and antibodies, 
although they do not appear on TEM images (Figure 19A). The diameter of the small clumps were 
comparable to the hydrodynamic radius of the sample measured using DLS, although it was expected 
that the diameter measured using TEM to be smaller than that of hydrodynamic radius. This size 
 
Figure 18. Size distribution of As33@SiO2@NPs measured using dynamic light scattering (DLS). Red and green 





difference may be due to the fact that As33@SiO2@NP samples could not undergo sonication before 
blotting on TEM grids, in an effort to prevent As33 denaturation, whereas DLS measurements were 
performed on filtered and sonicated samples. Nevertheless, some unconjugated silica-coated NPs 
were also observed under TEM, as spacing was not observed between the NPs (Figure 19B). 
 
3.3 Designing a New Phantom 
 A two-layer well phantom was designed to position multiple NP samples within the sensitive 
region of the RF coil of the MRI system for relaxivity measurements (Figure 13A). This holder 
would have allowed for imaging of eight samples simultaneously. However, reproducible data could 
not be obtained using the two-layer design and a single-layer well holder phantom was built instead 
to hold only four samples (Figure 13B). Different conditions (Conditions 1-6 in Figure 20A) of 
solutions with varied iron concentration were used to study the effectiveness of the phantom, to 
 
Figure 19. Transmission electron micrograph of A) As33 conjugated silica-coated iron oxide nanoparticles 
(NPs) and B) un-conjugated nanoparticles. As33-conjugated NPs were 32±7 nm (n=25) in diameter and have 
regular spacing between NPs. Small clumps of As33-conjugated NPs are 110±20 nm. Un-conjugated NPs were 
found in small clumps. Orange arrows point to phosphate salt-covered NPs, where as blue arrows point to 








 T2 Relaxation Time (ms) 
Mean ±Std. Error 
Condition ID 96-Well Phantom 
(n=3) 
PCR Tube Phantom 
(n=3) 
3 53±0 102±9 
4 93±2 117±9 
5 87±4   95±5 
6 96±7 105±5 
7 - 114±8 
8 - 112±3 
	  
Figure 20. A) Combination of Fe concentrations of iron oxide NP solutions used for studying the new phantom. 
B) T2 relaxation time of 0.436 M Fe solution in the two phantom designs.  
ensure that T2 relaxation times of the same NP sample (e.g. the yellow dot in Figure 20A) could be 
measured reproducibly using the phantom. A one-way ANOVA of T2 relaxation times of an FexOy 
NP solution with an [Fe2+/3+] of 0.436 M revealed a statistically significant difference in its T2 
relaxation time when imaged in conditions 1-6 outlined in Figure 20A (F (3, 8) = 24.092, p <0.001). 
This one-way ANOVA suggested that the iron oxide NPs in different wells were interacting with 
each other in the presence of an external magnetic field and the phantom was not suitable for imaging 





 In order to minimize the effects of NP interaction, the cross-sectional volume of NP solution 
in the phantom was reduced and the distance between samples was increased by designing a phantom 
to hold samples in PCR tubes (Figure 13D). A one-way ANOVA of T2 relaxation times of a FexOy 
NP solution with an [Fe2+/3+] of 0.436 M Fe2+/3+ did not find a statistical difference between the T2 
relaxation times of the sample in all conditions outlined in Figure7 (F (5, 13) = 1.388, p =0.291). The 
results indicated that at an iron concentration <0.436 M, the phantom could be used study four NP 
samples. Since NP cellular uptake studies are performed at nanomolar ranges, the new phantom was 
suitable for studying particle cellular uptake.  
 
3.4 Magnesium Content and the Number of Tumor Cells  
 CAPAN-2 and BxPC-3 cells contain relatively stable levels of Mg2+ over time, so the amount 
of Mg2+ ions in a cell pellet is linearly correlated with the number of cells in a pellet formed by cells 
from the same cell line.53 Two wavelengths of observation were compared in ICP-OES to determine 
	  
Figure 21. ICP-OES determination of Mg2+ content in cell pellets of known sizes at two characteristic 
wavelengths of magnesium: A) λ=279.099 nm and B) λ=285.024 nm. λ=285.024 nm was chosen in 






the appropriate wavelength for measuring Mg2+content of tumor cells.  
 Although the R2 value of the standard curve at both wavelengths are well above 0.90 for both 
cell lines, λ=279.099 nm occasionally provided intensity values below detection limit at lower Mg2+ 
concentrations. As a result, a wavelength of 285.024 nm was used in subsequent measurement of 
magnesium content in cells.  
 
3.5 Cellular Uptake 
 3.5.1 2D Cell Culture 
 Using CAPAN-2 cells as negative control and excess silica-coated NPs in CAPAN-2 cells as 
positive control, a decrease in T2 relaxation time in CAPAN-2 cells after exposure to 
As33@SiO2@NPs compared to that of only CAPAN-2 cells suggest FexOy NPs uptake. To quantify 
the number of NP uptake per cell, the amount of Fe2+/3+ and Mg2+ in the sample were determined 
from ICP-OES. The amounts of Mg2+ in the sample were correlated to the number of cells in the 
sample using standard curves established in Section 3.4. The number of NPs in the sample was 
calculated by first correcting for the amount of Fe2+/3+ in a comparable number of cells (assuming the 
Fe2+/3+ level in each cell did not fluctuate significantly over time) to find the net mass of iron in the 
sample that is attributed to NPs. Using a mass of 6.4x10-15 mg Fe2+/3+ per NP (assuming equal 
amounts of FeO and Fe2O3, as the percentage of FeO or Fe2O3 in the NP core is unknown) and 
assuming that iron oxide cores are 15 nm spheres, the number of NPs in the sample could be 
calculated (Personal Communications: Nolan Flynn). After dividing the number of NPs by the 
number of cells in the sample, approximately 530 antibody-conjugated NPs were found per cell, 
which is about six times higher than silica-coated NPs uptake in 2-D cell culture even in silica-NP 






3.5.2 3-D Cell Culture  
Before imaging via MRI, tumor cells were exposed to NPs for two hours before (0 hr), at the 
beginning of (5 hr), or after (36 hr) tumor spheroid formation. CAPAN-2 cells subjected to NPs with 
or without silica and antibody showed a large decrease in T2 relaxation time at all three time points 
of tumor spheroid formation (0, 5, 36hr). On the other hand, BxPC-3 cells showed a smaller decrease 
in T2 than did CAPAN-2 cells when the spheroid was grown for 0 or 5 hr in the presence of silica-
coated NPs and after spheroid formation in the presence of As33-conjugated SiO2@NPs (Table 2). 
Even in the absence of As33, silica-coated NPs were able to penetrate into both types of cells. This 
	  
B.  
Conditions #cells imaged Net mg of Fe NP /cell 
CAPAN-2 3.6x 106 - - 
SiO
2
@NP 3.7x106 4.68x10-5 90 
As33-SiO
2
@NP 1.5x106 5.02x10-5 530 
	  
Figure 22. Some evidence of NP cellular uptake was found by exposing 2D cell culture of CAPAN-2 cells 
to NPs for 1.5 hr and imaging the cell suspension using MRI. A) T2 relaxation times of CAPAN-2 cells, 
cells exposed to silica-coated NPs, and cells exposed to As33-conjugated silica-coated NPs. B) Average number 





may be because iron oxide cores were around 15 nm and silica-coated NPs were about 23 nm in 
diameter. These small sizes could have allowed these NPs to enter cells via non-specific endocytosis 
or pinocytosiss, as some tumor cells tend to take up NPs smaller than 100 nm in diameter, with an 
optimal uptake diameter of around 45 nm.30 Since silica-coated NPs are bigger than NP cores, 
making them closer to 45 nm, it was expected that more silica-coated NPs could enter cells than bare 
NPs (assuming minimal contribution from particle surface charge). Moreover, it was expected that 
more NPs, whether or not silica-coated or conjugated with As33, could enter CAPAN-2 cells than 
BxPC-3 cells, as CAPAN-2 cells pack more loosely than BxPC-3 cells during spheroid formation, 
therefore providing more surface area for NP cellular uptake to occur.   
Immediately after MRI, cell pellets were digested in HNO3 for analysis via ICP-OES to 
quantify NP cellular uptake. As33-conjugated SiO2@NPs were not found in either cell line prior to 
spheroid formation (absence of red bar at 0 hr in Figure 23), although bare NPs and SiO2@NPs were 
present. No NPs were found in BxPC-3 cells at this time point. At the beginning of tumor spheroid 
formation (5 hr), only As33-conjugated NPs were able to enter CAPAN-2 cells, whereas all three 
types of NPs, whether or not silica-coated or conjugated with As33, were found in BxPC-3 cells. At 
36 hr, a higher amount of As33@ SiO2@NPs was found in CAPAN-2 cells than BxPC-3 cells after 
spheroid formation. At this time point, uptake of un-conjugated silica-coated NPs was also observed 
Table 2. T2 relaxation times of cell pellets exposed to differentially functionalized NPs and their controls.   
 
 
T2 (ms)  
in CAPAN-2 Cells 
T2 (ms) 
in BxPC-3 Cells 
Conditions 0 hr  5 hr  36 hr  0 hr  5 hr  36 hr  
Cells 207.1  200.6  186.5  273.8  250.4       - 
+NP 96.3  119.6  199.9  225.8  186.7       - 
+SiO2@NP 48.2  109.7  143.9  97.5  140.2  223.7  






in CAPAN-2 cells, but not in BxPC-3 cells. The amount of silica-coated NPs found in CAPAN-2 
cells after spheroid formation suggested that although As33-conjugated SiO2@NPs were able to enter 
CAPAN-2 cells, the effect may not have been due to the presence of As33 or receptor-mediated 
endocytosis, but rather because CAPAN-2 cells preferentially take up silica-coated NPs. However, 
	  
	  
Figure 23. Particle cellular uptake in CAPAN-2 and BxPC-3 cells determined via ICP-OES. 
Calculations assumed that each NP has a spherical core of 15nm. Time since seeding is the time at which NP 

















































replicates would be needed to confirm these observations. 
MRI results are consistent with ICP-OES results at 36 hr, but not at 0 or 5 hr (Table 2, Figure 
23). For the cells exposed to NPs at 36 hr, ICP-OES showed that the CAPAN-2 cells had higher iron 
concentrations than the BxPC-3 cells and the MR T2 relaxation times for the CAPAN-2 cells were 
lower for all forms of NPs, as expected.  At 0 hr, it was expected that CAPAN-2 cells would have a 
higher amount of Fe2+/3+ than BxPC-3 cells for As33-conjugated NPs, and therefore lower T2 
relaxation times. Although it was observed that T2 relaxation times of CAPAN-2 cells were lower 
than those of BxPC-3 cells for all forms of NPs, ICP-OES results did not show uptake of 
As33@SiO2@ NPs by the CAPAN-2 cells, or uptake of silica-coated and As33@SiO2@ NPs by the 
BxPC-3 cells,.   
A similar discrepancy was observed at the 5 hr time point, where a decrease in T2 of 
CAPAN-2 cells exposed to SiO2@ NPs and As33@SiO2@ NPs compared to the T2 of just those 
cells suggested uptake of bare and silica-coated NPs in CAPAN-2 cells, while again, the ICP-OES 
did not. Moreover, at the 5 hr time point, lower values of T2 in bare NP-treated and As33@SiO2@ 
NPs-treated BxPC-3 cells were expected in comparison to CAPAN-2 cells, as there was more 
Fe2+/3+- found in BxPC-3 cells via the ICP-OES measurements. As shown in Table 2, however, the T2 
values of BxPC-3 cells were not lower than those of CAPAN-2 cells under these conditions. 
These discrepancies may have been due to the fact that after MRI and prior to acid digestion, 
the supernatant from the cell pellets was removed. It is possible that some cells with NP uptake lysed 
during the process of MRI. The lysis of cells, along with weakly-bound NPs on cell surfaces, could 
have caused loss of Fe2+/3+ during supernatant removal prior to ICP-OES analysis, resulting in a 
lower Fe2+/3+- concentration determined from ICP-OES. In addition, while the total number of NPs 





dependent on how the spheroids were formed. It is possible that, by chance, the way the spheroids 
settled into a pellet left space for water to pack between each spheroid, increasing T2 of the slice, 
making the voxel chosen for MRI appear to contain fewer nanoparticles than a voxel in a different 




















4 Discussion and Suggestions for Future Work 
 This thesis explored the synthesis of antibody-conjugate silica coated FexOy NPs, tested a 
design for a new MRI phantom for imaging live tumor cells, and quantified NP cellular uptake via 
2D and 3D cell culture. This investigation focused on three areas:  
1. As33@SiO2@NPs were successfully synthesized by building a PEG-protein A/G linker, 
attaching the linker to silica-coated NPs, and attaching As33 onto the linker. The presence of 
silica on NP surface was confirmed via FT-IR and the diameter was measured using TEM. 
The thickness of the silica coating was 2 nm. Approximately two antibodies were found on 
each NP via ELISA. As33@SiO2@FexOy NPs have a range of diameters under TEM and 
DLS, where the majority of the NPs are 109±7 nm.   
2. A new MRI phantom was designed and built for imaging cell pellets. Although phantoms 
containing wells from standard 96-well plates were unsuitable for imaging NPs, a holder for 
PCR tubes designed to encompass the most homogeneous part of the magnetic field was 
suitable for imaging NPs with a Fe2+/3+ concentration <0.423 M. Since NP cellular uptake 
studies use Fe concentrations in the nanomolar range, the PCR phantom was deemed suitable 
for studying NP cellular uptake. 
3. Some evidence of cellular uptake of As33@SiO2@NP was found in 2D and 3D tumor 
cell culture of CAPAN-2. A decrease in T2 relaxation time, indicating the presence of FexOy 
NPs in cells, was found in CAPAN-2 after NP exposure. ICP-OES analysis of Mg2+ and 
Fe2+/3+ content of cells estimated 2300 NP per CAPAN-2 cell when As33@SiO2@NP 
exposure took place after spheroid formation, whereas only 920 were found per BxPC-3 cell. 
However, a comparable number of silica-coated NPs were found in CAPAN-2 cells, 





The number of NPs found in our study is theoretically possible as the NPs take up less than 
0.02% of the cell volume and the total number of NPs found inside cells was less than 2% of the 
available NPs in the environment. Most published studies of NP uptake in cells utilize fluorescence 
microscopy (e.g. confocal) or a staining method to semi-directly quantify the amount of NPs in the 
cells, whether in 2 or 3D cell culture.54 Whereas NP uptakes have seldom been studied in CAPAN-2 
cells, SPIOs have been quantified in vivo in BxPC-3 cells using atomic absorption spectrometry or 
Prussian blue staining.55 Although a number of studies did quantify the concentration of the contrast 
agent (i.e. Fe2+/3+), no known study estimated the number of NPs per cell from these measurements.55-
56  
The next steps of this research project should investigate other methods of NP 
characterization. While attempts were made to measure the T2 relaxivity value of silica-coated NPs 
before antibody-conjugation, R2 remained undetermined as the Fe2+/3+ content of NPs may be under-
estimated by ICP-OES.12 ICP-MS may be a potential alternative for quantifying Fe2+/3+ contents in 
silica-coated NPs, if the quantity of NPs produced would allow. Moreover, there is not a method to 
separate antibody-conjugated NPs from unconjugated ones. Previously work by Nagalla attempted to 
use a modified gel-electrophoresis for separation, but had limited success as the size differences 
between antibody-conjugated NPs and silica-coated NPs is quite small.13 Perhaps the use of size-
exclusion chromatography would be a viable alternative for purifying antibody-conjugated NPs.  
Moreover, the particle surface charges of silica-coated and antibody-conjugated silica-coated NPs 
remain undetermined.  
The main area of future focus for this study is to repeat the cellular uptake of antibody-
conjugated NPs. There are several potential factors responsible for the comparable uptake of silica-
coated and antibody-conjugated SiO2@NPs in CAPAN-2 cells observed in this study. First, the size 





nm tended to have higher degree of NP cellular uptake, the amount of silica-coated NP uptake in 
CAPAN-2 cells may be due to their smaller diameter.30 Second, antibody-conjugated NPs had a 
range of sizes. Aggregation of NPs may have affected the ability of As33 to bind to GPA33 in order 
for particle uptake to take place. Moreover, the number of functional GPA33 present on CAPAN-2 
cells was decreased due to physical scraping from culture flasks, and would not have recovered at 
seeding (0 hr) or the beginning of spheroid formation (5 hr). This decrease in the number of function 
GPA33 could have resulted in varied uptake of NPs observed in CAPAN-2 cells before (0 hr) and at 
the beginning of spheroid formation (5 hr). At spheroid formation (36 hr), the number of GPA33 in 
CAPAN-2 cells was expected to have recovered to normal levels for optimal NP uptake to occur, 
which led the expected result of As33@SiO2@NP uptake in CAPAN-2 cells (Figure 23). On the 
other hand, the preferred mechanism of NP uptake in BxPC-3 cells remained unclear, although it 
does not express GPA33. The large amount of NP uptake observed at the beginning of spheroid 
formation (5 hr) in BxPC-3 cells may have been specific to BxPC3 cells, but it is uncertain without 
studying NP another in another cell line that does not express GPA33.  
To address potential remaining issues, future work should focus on reproducing the synthesis 
of As33@SiO2@NPs and particle cellular uptake results. Since NP cellular uptake is highly 
dependent on the size of the NP, it may be ideal to use silica-coated NPs with comparable 
hydrodynamic radius as the As33@SiO2@NPs in cellular uptake studies. To conclude definitely that 
the NPs did not just bound to the cell surface and in fact entered cells, it would also be useful to 
conduct a control experiment to determine the degree of cellular uptake versus cell binding by 
performing the same cell uptake experiment at 4 oC. Since endocytosis is a temperature dependent 
event, NPs should not be able to enter a cell at 4 oC. The observation of NPs in cell digests when NP 
exposure took place at 4 oC would indicate that a significant amount of NPs remained bound on the 





 Efforts should also be made to explore the degree of NP penetration in tumor spheroids. 
Since the mAb As33 used in this study is tagged with a pH-dependent fluorophore, it is possible to 
observe NP cellular uptake via fluorescence microscopy or alternatively, via an iron oxide staining 
method such as Prussian blue.57 It may be worthwhile to seed fewer numbers of cells during the 
spheroid culturing, observe cellular uptake of NPs in different sized spheroids, and compare that with 
particle uptake in spheroids over growth periods, to ensure that the number of GPA33 on the 
CAPAN-2 cell surface has recovered for sufficient targeting to occur. 
There exist many avenues for the continuation of this project. When mono-dispersed, 
As33@SiO2@NPs are synthesized, boronated poly-GL peptides could be attached to the silica 
surface to achieve the therapeutic potential of NPs. Moreover, the quantification of relaxivity values 
of these NPs post synthesis will determine whether they are indeed suitable for clinical use, as T2 


















Appendix I: Protocol 
I.1 Nanoparticle Uptake by Tumor Cells 
 
Materials 
• 2 jars of T150 of CAPAN2 or BxPC3 cells, at 70% confluency 
• RMPI media without antibiotic, phenyl red, and FBS, with 0.5%BSA 
• RMPI media without antibiotic, phenyl red, and FBS, with 0.5%BSA, 2% methyl cellulose 
• One 3D Hanging droplet plate for each cell type 
• Cell scraper 
• Nanoparticle solutions 
• Hematocytometer, 20% Trypan blue  
 
1. Use a cell scraper to scrape cells from the flask. 
2. Wash cells twice with 10mL of PBS (RT). Centrifuge at 1000rpm for 3min to collect each 
time. 
3. Dilute each T150 flask in 12mL of media. This should give about 1x10e6 cells per mL. Use a 
hematocytometer to count live cells to make sure and make dilutions as necessary. 
4. Resuspend all cells in 5mL of RMPI media without antibiotic, phenyl red, and FBS, with 
0.5%BSA (for BxPC3 cells). For CAPAN-2 cells, use RMPI media without antibiotic, phenyl 
red, and FBS, with 0.5%BSA, 2% methyl cellulose. This will give about ~200,000 cells per 
40uL  
5. Seed about 200, 000 cells per well using RMPI w/o antibiotic, phenyl red, and FBS, with 
0.5%BSA 
6. Let cells sit in 37 oC incubator, 5% CO2 for 0hr, 5hr 24hr for formation of spheres 
7. During this time, make dilutions for particle exposure so that final concentration of Fe2+/3+ in 
the drop is around 2nM.  
8. Incubate cells with NPs for 2hrs by adding the NP solutions of appropriate volume into the 
droplet individually according to the layer out below. Pink: As33@SiO2@NP, blue: 
SiO2@NP, yellow: NP cores, white: do nothing. 
 
 
9. Collect the spheres in a clean 96-well assay plate, by adding 50uL of PBS onto each droplet. 
10. Put 8-12 spheroids of exposed to the same conditions into a PCR tube (label/use different 
colors). 





12. Remove supernatant.  
13. Add 150uL of PBS and flick the pellet around a little. Careful to not destroy the pellet. 
14. Centrifuge at 1000rpm for 3min.  
15. Repeat steps 11-13 two more times.  
16. Ready for MRI. 
17. After imaging, remove supernatant above cells and add 150uL of 69% HNO3 (Omni-grade) 
to digest cell pellets. 
18. Let cell pellets sit in acid overnight. Vortex to mix well if necessary.  
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